Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of chronic autoimmune disease, systemic, associated with high morbidity and functional disability. Concerning to the clinical and histopathological features, the MII can be classified into polymyositis (PM), dermatomyositis (DM), juvenile dermatomyositis, myositis, a corpuscle, myositis associated with malignancy and myositis associated with other collagen diseases.In relation to the metabolic syndrome (PMS), it is a multifactorial disease of elevated prevalence. It is a series of disorders characterized by biochemical and physiological change in fasting glucose levels, central obesity, dyslipidemia and hypertension.In the few available studies, the prevalence of PMS in systemic autoimmune rheumatic diseases ranges from 14 to 62.8% and thus higher than in the general population. This high prevalence suggests that the presence or treatment of autoimmune diseases systemic influences the risk of developing PMS.However, to our knowledge, no studies in the literature, assessing the prevalence, as well as the impact of SPM in IIM, which motivated us to conduct this study.
News published in Agência FAPESP Newsletter about the scholarship: